Scarica l'app Stockscreener
2.74
5.84%
-0.17
Dopo l'orario di chiusura:
2.76
0.02
+0.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CABA Giù?
Forum
Previsione
Precedente Chiudi:
$2.91
Aprire:
$2.85
Volume 24 ore:
7.05M
Relative Volume:
1.45
Capitalizzazione di mercato:
$464.55M
Reddito:
-
Utile/perdita netta:
$-175.43M
Rapporto P/E:
-1.3883
EPS:
-1.9736
Flusso di cassa netto:
$-143.28M
1 W Prestazione:
-21.26%
1M Prestazione:
-2.14%
6M Prestazione:
-17.47%
1 anno Prestazione:
+57.47%
Intervallo 1D:
$2.69
$2.875
Intervallo di 1 settimana:
$2.69
$3.60
Portata 52W:
$1.72
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Nome
Cabaletta Bio Inc
Settore
Industria
Telefono
(267) 759-3100
Indirizzo
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.74 | 493.38M | 0 | -175.43M | -143.28M | -1.9736 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Ripresa | Jefferies | Buy |
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-02-05 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Iniziato | William Blair | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | Stifel | Buy |
| 2023-09-05 | Iniziato | Citigroup | Buy |
| 2023-07-18 | Iniziato | Guggenheim | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-01-08 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Iniziato | Cowen | Outperform |
| 2019-11-19 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Cabaletta Bio Inc Borsa (CABA) Ultime notizie
Cabaletta Bio at cantorfitzgerald healthcare conference: safety and scale By Investing.com - Investing.com Canada
Cactus Cuts Q3 Pressure Control Outlook on Expected Double-Digit Revenue Decline - Minichart
Cabaletta Bio Inc (NASDAQ: CABA) Share Price, CABA Stock News, CABA Share Price & Updates - Kalkine
Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely? - Moomoo
Cabaletta Bio Takes Autoimmune Cell Therapy Pitch to Investors - MyChesCo
CABA Stock Price and Chart — NASDAQ:CABA - TradingView
TD Cowen Maintains Cabaletta Bio(CABA.US) With Buy Rating - Moomoo
CABA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $16 - GuruFocus
Cabaletta Bio to Participate in Upcoming Investor Conferences - Yahoo Finance
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cabaletta Bio Inc. (CABA) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Cabaletta Bio Inc (CABA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cabaletta (CABA) Earnings Reading: EPS Lands Above Forecast in the Current Update; Post-Report: Shares Finish 0.96% Down in the Available RecordProfit Growth Outlook - vinanet.vn
Blue Owl Capital Holdings LP Acquires New Holdings in Cabaletta Bio, Inc. $CABA - MarketBeat
WuXi Bio to offload chromatography unit; Cabaletta names another CDMO partner - Endpoints News
Cabaletta Targets 2027 BLA as Cell Therapy Trials Advance - MyChesCo
Cabaletta Bio (NASDAQ:CABA) Trading 10.3% HigherShould You Buy? - MarketBeat
Norges Bank Initiates New Position in Cabaletta Bio (CABA) With 8.7 Million Share Purchase - GuruFocus
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Cabaletta Bio (CABA) Rallies 5% as Biotech Sentiment ImprovesForce Index - vinanet.vn
HC Wainwright Raises Earnings Estimates for Cabaletta Bio - MarketBeat
Cabaletta Bio (CABA) Reports Promising Phase 1/2 Data Amid Unpro - GuruFocus
668,563 Shares in Cabaletta Bio, Inc. $CABA Bought by GSA Capital Partners LLP - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wells Fargo Sticks to Their Hold Rating for Cabaletta Bio (CABA) - The Globe and Mail
Cormorant Asset Management (CABA) discloses 10M-share Cabaletta Bio stake - Stock Titan
CABA Maintained by Wells Fargo -- Price Target Lowered to $3.00 - GuruFocus
Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - MarketBeat
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Cabaletta Bio Releases Q2 2026 Financial Results - AlphaStreet
Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress - Investing.com
Why is Cabaletta Bio stock sliding today? By Investing.com - Investing.com Australia
Why is Cabaletta Bio stock sliding today? - Investing.com
Cabaletta Bio Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Cabaletta Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cabaletta Bio (CABA) Q2 Earnings Beat Expectations; Market Focuses on Growth Potential Despite Losses - GuruFocus
Form 8K Cabaletta Bio Inc For: 13 August By Investing.com - Investing.com Nigeria
Cabaletta Bio Q2 net loss widens as R&D costs rise - TradingView
Cabaletta Bio, Inc. 2Q 2026: Net loss $(51.0)M, EPS $(0.34) — 10-Q Summary - TradingView
Cabaletta Bio (CABA) lifts cash to $225M while advancing rese-cel toward BLA - Stock Titan
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio (NASDAQ: CABA) lifts cash to $225M while advancing CAR-T trials - Stock Titan
Cabaletta Bio reports Q2 2026 net loss of $51.0M; cash position $225.1M supports operations into mid-2027 - TradingView
CABA Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Clinical-Stage FocusShare Repurchase Impact - Vinanet
Adage Capital discloses 8.43% Cabaletta Bio (CABA) stake including warrant shares - Stock Titan
Cabaletta Bio (CABA): Norges Bank reports 5.382% ownership of 8.78M shares - Stock Titan
Cabaletta Bio, Inc. expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Cabaletta Bio Inc (CABA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cabaletta Bio, Inc. Stock 12‑Month Price Target Raised to $14.71, Implies 427% Upside - TradingView
Cabaletta Bio Inc Azioni (CABA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):